• Early FDA approval of Somfit D positions Compumedics to scale US home sleep testing market
• OrionMEG global expansion targeting $13.6B neuroscience imaging market
• SaaS-driven margin expansion from 770,000+ sleep and neurology studies

Compumedics Limited, a leading global medical technology company in sleep diagnostics, brain imaging and neuro-monitoring, has successfully completed a $2.15 million placement to fund the acceleration of its Somfit D commercialization and increase manufacturing capacity for its OrionMEG brain imaging platform. The placement was supported by existing, new institutional and sophisticated investors. The funds will be used to fast-track Somfit D production and working capital ahead of expected revenue in the second half of FY26, as well as increase in-house and partner manufacturing capacity to support growing global demand for OrionMEG. The company is also using the capital to support logistics, customer onboarding and commercial execution across the US, Europe and Asia as it transitions from pilot adoption to full-scale rollout of Somfit and OrionMEG. Compumedics is entering its most significant commercial expansion phase, underpinned by three strategic growth pillars: scaling the US home sleep testing market with Somfit, global expansion of its breakthrough OrionMEG functional brain imaging platform, and SaaS-driven margin expansion from its sleep and neurology platforms. The company has reaffirmed its FY26 guidance of revenue over $70 million and EBITDA of around $9 million.

Compumedics reaffirms FY26 guidance of revenue over $70 million and EBITDA of around $9 million.

Compumedics is positioned to deliver not only operational performance but a structural valuation re-rating against peers as it executes on its FY26 plans, strengthens its US sales leadership, and continues Board renewal.